[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02507583 : Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma|
|Ages||Min: 18 Years Max: N/A|
- Documentation by MR of a gadolinium-enhancing intraparenchymal mass consistent with
- Frozen section diagnosis of WHO Grade IV glioma, confirmed with permanent section and
immunopositive for IGF-1R.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or a
Karnofsky Performance Score (KPS) of at least 60.
- Must be 18 years of age or older.
- Must sign an approved informed consent.
- Hemodynamically stable, consistent with Standard of Care values for patients
undergoing elective tumor resection.
- Females who are pregnant, nursing, or not inclined to use adequate contraceptive
methods if necessary to prevent pregnancy during the study.
- An active second primary malignancy with the exception of basal cell or squamous cell
- Major concomitant medical illness inclusive of severe chronic obstructive pulmonary
disease, multiple sclerosis, symptomatic coronary artery disease, heart failure,
recent major cerebrovascular accident, brittle diabetes, renal dialysis, end stage
liver disease, labile hypertension, or any autoimmune disorder.
- A history of heparin-induced thrombocytopenia or hypersensitivity to heparin,
enoxaparin, or pork products.
- An abnormal International Normalized Ratio (INR) of greater than 1.3, if repeatable
and refractory to correction by routine methods.
- Documented deep venous thrombosis
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02507583
| Link to official Clinicaltrials.gov listing